Literature DB >> 21984193

Autoimmunity as a prognostic factor in sporadic adult onset cerebellar ataxia.

R Sivera1, N Martín, I Boscá, T Sevilla, N Muelas, I Azorín, J J Vílchez, M Bolonio, E Donat, C Ribes-Koninckx, L Bataller.   

Abstract

Cerebellar adult onset ataxia is a heterogeneous condition. The aim of this study was to ascertain if there is a heightened autoimmune background in patients with sporadic cerebellar ataxia of unknown origin, and if autoimmunity correlates with a more rapid evolution of the ataxia. We selected patients with sporadic progressive adult onset cerebellar ataxia with a follow-up of >5 years. As controls we included 43 patients with genetically demonstrated hereditary ataxia. All patients were tested for a panel of neuronal (onconeuronal, glutamate-decarboxylase [GAD], IgG/IgA transglutaminase 6 antibodies) and systemic non-neuronal antibodies (including IgG/IgA gliadin and transglutaminase 2, thyroperoxidase, thyroglobulin, antinuclear, striational, smooth muscle, mitochondrial, liver kidney microsomal, and parietal gastric cells antibodies). Correlation between the antibodies and disease progression was studied with Cox regression models and Kaplan-Meier plots. Forty-four patients were included. All patients were negative for onconeuronal or GAD antibodies. There were no significant differences between patients and controls in the prevalence of transglutaminase 6, 2, gliadin, or thyroid antibodies. However, when we studied the panel of systemic non-neuronal autoantibodies as a group, antibodies were more frequent in patients with sporadic ataxia (p = 0.018). The presence of one or more systemic non-neuronal antibodies correlated with a faster evolution to stage 2 (loss of independent gait) (p = 0.03) and shorter survival (p = 0.03) in patients with sporadic ataxia. We conclude that there is probably a heightened autoimmune background in some patients with sporadic cerebellar ataxia of unknown origin. The presence of systemic non-neuronal autoantibodies is a prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984193     DOI: 10.1007/s00415-011-6266-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Cerebellar ataxia associated with neuroendocrine thymic carcinoma and GAD antibodies.

Authors:  L Bataller; C Valero; R Díaz; A Froufe; A Garcia-Zarza; T Ribalta; J J Vilchez; A Saiz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06       Impact factor: 10.154

Review 2.  Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.

Authors:  V Violante; A Luongo; I Pepe; S Annunziata; V Gentile
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

3.  Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis.

Authors:  M Selim; D A Drachman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-07       Impact factor: 10.154

4.  The natural history of degenerative ataxia: a retrospective study in 466 patients.

Authors:  T Klockgether; R Lüdtke; B Kramer; M Abele; K Bürk; L Schöls; O Riess; F Laccone; S Boesch; I Lopes-Cendes; A Brice; R Inzelberg; N Zilber; J Dichgans
Journal:  Brain       Date:  1998-04       Impact factor: 13.501

5.  The aetiology of sporadic adult-onset ataxia.

Authors:  M Abele; K Bürk; L Schöls; S Schwartz; I Besenthal; J Dichgans; C Zühlke; O Riess; T Klockgether
Journal:  Brain       Date:  2002-05       Impact factor: 13.501

Review 6.  Sporadic ataxia with adult onset: classification and diagnostic criteria.

Authors:  Thomas Klockgether
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

7.  Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.

Authors:  Marios Hadjivassiliou; Pascale Aeschlimann; Alexander Strigun; David S Sanders; Nicola Woodroofe; Daniel Aeschlimann
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

8.  Prevalence of antigliadin antibodies in ataxia patients.

Authors:  M Abele; L Schöls; S Schwartz; T Klockgether
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

Review 9.  Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly.

Authors:  M Ramos-Casals; M García-Carrasco; M P Brito; A López-Soto; J Font
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics.

Authors:  Marios Hadjivassiliou; Richard Grünewald; Basil Sharrack; David Sanders; Alan Lobo; Clare Williamson; Nicola Woodroofe; Nicholas Wood; Aelwyn Davies-Jones
Journal:  Brain       Date:  2003-03       Impact factor: 13.501

View more
  5 in total

Review 1.  Acquired ataxias: the clinical spectrum, diagnosis and management.

Authors:  Wolfgang Nachbauer; Andreas Eigentler; Sylvia Boesch
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

2.  Clinical Features and Neuroimaging Findings of Neuropil Antibody-Positive Idiopathic Sporadic Ataxia of Unknown Etiology.

Authors:  Akira Takekoshi; Akio Kimura; Nobuaki Yoshikura; Isamu Yamakawa; Makoto Urushitani; Katsuya Nakamura; Kunihiro Yoshida; Takayoshi Shimohata
Journal:  Cerebellum       Date:  2022-09-03       Impact factor: 3.648

3.  Gluten ataxia is better classified as non-celiac gluten sensitivity than as celiac disease: a comparative clinical study.

Authors:  Luis Rodrigo; Carlos Hernández-Lahoz; Eugenia Lauret; Maria Rodriguez-Peláez; Miroslav Soucek; Rachele Ciccocioppo; Peter Kruzliak
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

4.  Serum antigliadin antibodies in cerebellar ataxias: a systematic review and meta-analysis.

Authors:  Chi-Ying Lin; Min-Jung Wang; Winona Tse; Rachel Pinotti; Armin Alaedini; Peter H R Green; Sheng-Han Kuo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-06-04       Impact factor: 10.154

5.  Anti-Homer-3 antibodies in cerebrospinal fluid and serum samples from a 58-year-old woman with subacute cerebellar degeneration and diffuse breast adenocarcinoma.

Authors:  Christof Klötzsch; Matthias Böhmert; Ruxandra Hermann; Bianca Teegen; Kristin Rentzsch; Andreas Till
Journal:  Neurol Res Pract       Date:  2022-07-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.